摘要
目的:探讨降钙素原在乳腺癌化疗后粒细胞减少伴发热患者中的临床应用价值。方法:回顾性分析2008年3月-2012年9月本院收治的118例乳腺癌化疗后中性粒细胞减少伴发热患者临床资料,根据患者临床症状、体征、病原及影像学资料,将患者分为感染组和发热原因不详组,分析两组血清降钙素原水平差异及血清降钙素原水平与患者年龄、化疗方案、发热程度和粒细胞缺乏的关系。结果:感染组血清降钙素原水平明显高于发热原因不详组(P<0.05);血清降钙素原表达差异与年龄、化疗方案、发热及粒细胞减少程度无关(P>0.05)。结论:血清降钙素原水平对于乳腺癌化疗后中性粒细胞减少伴感染的早期诊断具有重要意义,且不受患者的年龄、化疗方案、发热程度和粒细胞水平影响。
Objective:To explore clinical value of procalcitonin in breast cancer patients with neutropenia associated with fever after chemotherapy. Method:The clinical data of 118 hospitalized patients with breast cancer associated with fever after chemotherapy from March 2008 to September 2012 were analyzed. The patients were divided into the infected group and the fever reasons unknown group according to clinical symptoms,signs,etiology. The relationship of serum procalcitonin levels were comparative analyzed between the two groups. The relationship of serum procalcitonin levels with age,chemotherapy scheme,heating degree and agranulocytosis levels were analyzed. Result:Serum procalcitonin levels in the infected group was significantly higher than the fever reasons unknown group(P〈0.05). Serum procalcitonin levels had nothing to do with age,chemotherapy scheme,heating degree and agranulocytosis levels(P〉0.05). Conclusion:Serum procalcitonin levels has a great significance for early diagnosis of infection in breast cancer patients with neutropenia associated with fever after chemotherapy,and it did not infected by patients age,chemotherapy scheme, heating degree and agranulocytosis levels.
出处
《中国医学创新》
CAS
2014年第27期63-65,共3页
Medical Innovation of China